CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02536183
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:36.785023+00:00
Published At: 2023-08-29T00:00:00+00:00
Record Updated At: 2023-08-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pediatric Cancer", "Solid Tumors", "Rhabdomyosarcoma", "Ewing Sarcoma", "Soft Tissue Sarcomas", "Osteosarcoma", "Neuroblastoma", "Wilms Tumor", "Hepatic Tumor", "Germ Cell Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-08-29"
protocolSection.identificationModule.nctId: "NCT02536183"
protocolSection.identificationModule.officialTitle: "A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox\u00ae) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.